Journal
JOURNAL OF CROHNS & COLITIS
Volume 15, Issue 9, Pages 1431-1442Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjab050
Keywords
Precision medicine; personalised medicine; inflammatory bowel diseases; disease prognosis; disease outcome; response to therapy
Categories
Ask authors/readers for more resources
The ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers in IBD, shed light on key questions in biomarker development, and discuss the potential for multi-omic data integration to make precision medicine a reality in IBD.
Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available